Ftse Mib
34.107,77
-0,13%
DAX
18.549,12
0,33%
S&P 500
5.187,67
0,00%
NASDAQ
16.302,76
-0,18%
Bitcoin
61.193,80
0,01%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE ADC Therapeutics SA (ADCT) ADC Therapeutics SA (ADCT) Notizie

ADCT

ADC Therapeutics (ADCT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:ADCT
DataOraFonteTitoloSimboloCompagnia
08/05/202422:07Edgar (US Regulatory)Form 8-K - Current reportNYSE:ADCTADC Therapeutics SA
07/05/202422:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ADCTADC Therapeutics SA
07/05/202422:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:ADCTADC Therapeutics SA
06/05/202413:30GlobeNewswire Inc.ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsNYSE:ADCTADC Therapeutics SA
06/05/202412:38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ADCTADC Therapeutics SA
06/05/202412:10GlobeNewswire Inc.ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/05/202412:00GlobeNewswire Inc.ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone LymphomaNYSE:ADCTADC Therapeutics SA
01/05/202422:05GlobeNewswire Inc.ADC Therapeutics Makes Grants to New Employees Under Inducement PlanNYSE:ADCTADC Therapeutics SA
01/05/202413:00GlobeNewswire Inc.ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024NYSE:ADCTADC Therapeutics SA
04/04/202413:00GlobeNewswire Inc.ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaNYSE:ADCTADC Therapeutics SA
03/04/202413:00GlobeNewswire Inc.ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024NYSE:ADCTADC Therapeutics SA
13/03/202412:03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNYSE:ADCTADC Therapeutics SA
13/03/202412:00GlobeNewswire Inc.ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/03/202413:15GlobeNewswire Inc.ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes SummitNYSE:ADCTADC Therapeutics SA
06/03/202413:00GlobeNewswire Inc.ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024NYSE:ADCTADC Therapeutics SA
05/03/202423:45GlobeNewswire Inc.ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual MeetingNYSE:ADCTADC Therapeutics SA
27/02/202413:00GlobeNewswire Inc.ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceNYSE:ADCTADC Therapeutics SA
04/01/202413:15GlobeNewswire Inc.ADC Therapeutics Regains Compliance with NYSE Continued Listing StandardsNYSE:ADCTADC Therapeutics SA
04/01/202413:00GlobeNewswire Inc.ADC Therapeutics Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
03/01/202402:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:ADCTADC Therapeutics SA
19/12/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:ADCTADC Therapeutics SA
18/12/202322:25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:ADCTADC Therapeutics SA
12/12/202311:15GlobeNewswire Inc.ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)NYSE:ADCTADC Therapeutics SA
20/11/202308:40PR Newswire (US)Sobi to present new data at ASH 2023 Annual MeetingNYSE:ADCTADC Therapeutics SA
15/11/202309:00GlobeNewswire Inc.Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of DirectorsNYSE:ADCTADC Therapeutics SA
07/11/202313:15GlobeNewswire Inc.ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing StandardsNYSE:ADCTADC Therapeutics SA
07/11/202313:00GlobeNewswire Inc.ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNYSE:ADCTADC Therapeutics SA
06/11/202313:00GlobeNewswire Inc.ADC Therapeutics to Participate in the Jefferies London Healthcare ConferenceNYSE:ADCTADC Therapeutics SA
02/11/202315:10GlobeNewswire Inc.ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual MeetingNYSE:ADCTADC Therapeutics SA
24/10/202313:00GlobeNewswire Inc.ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023NYSE:ADCTADC Therapeutics SA
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:ADCT

La tua Cronologia

BIT
BPE
Bper Banca
BIT
NEXI
Nexi S.p.A
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BAMI
Banco BPM
BIT
STLAM
Stellantis NV
BIT
LDO
Leonardo
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
SRG
Snam
BIT
RACE
Ferrari NV
BIT
TRN
Terna Trasmissione Elett...
BIT
TEN
Tenaris
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network